The interleukin (IL-4) and IL-13 inhibitor dupilumab is an effective treatment for patients with severe chronic rhinosinusitis with nasal polyps, two new studies show.

The results of the trials — one which ran for six months and one for a year — showed that patients on fortnightly dupilumab subcutaneous injections had a greater reduction in nasal polyp size than those on placebo.